Liposomal Irinotecan for Malignant Ascites
Part of Cancer clinical trials.
This trial tests a drug called liposomal irinotecan, given alone or with other medications, to treat fluid buildup in the belly caused by digestive system cancers. It's for people who have already tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed digestive system cancer that has spread to the belly and caused moderate to large fluid buildup (ascites).
- You have tried at least one prior treatment for your cancer or for the fluid buildup.
- You are able to take care of yourself most of the day (ECOG score 0-2).
- Your major organs, like your liver, kidneys, and bone marrow, are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
This study tests a new form of the chemotherapy drug irinotecan (liposomal irinotecan) for people with metastatic colorectal cancer whose first treatment with oxaliplatin-based therapy has stopped working. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
Hear when a new Malignant Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.